Student IP writing competition from the Virginia Bar

Intellectual Property Section Intellectual Property Law Student Writing Competition

For more than 40 years, the Intellectual Property Section of the Virginia State Bar has striven to advance the quality of intellectual law practice in the Commonwealth of Virginia. The Intellectual Property Law Student Writing Competition (the “Competition”) seeks to promote academic debate and the dissemination of ideas and scholarly writing in the field of intellectual property. The Competition is sponsored by the Intellectual Property Section of the Virginia State Bar. All articles submitted will receive consideration for publication by the Section to its membership. Student authors entering the competition thereby authorize such publication. The Section publication’s editors reserve the right to make editorial revisions to the author’s article prior to publication on the Section’s website. Prize $5,000 and publication on the Section’s website.

If the Section determines that a second article is of sufficient quality, it may award a second prize of $2,500 for that article, as well. Eligibility The Competition is open to all students enrolled and in good standing during the 2015-16 academic year (including December 2015 graduates) at (i) any Virginia law school, or (ii) a law school outside Virginia as a resident of Virginia (with proof of residency). Articles must have been written solely by the entrant while enrolled in law school. Topic & Format Articles must relate to an intellectual property law issue or the practice of intellectual property law. Preference may be given to topics demonstrating particular relevance to contemporary events, addressing unsettled issues of law, or presenting novel and unique perspectives. Articles should be approximately 25 to 40 typed pages (including footnotes) in length. Entries must be double-spaced, in at least 12-point font, with one-inch margins and numbered pages. Citations should conform to the Bluebook. Entries must be submitted electronically in WordPerfect or Microsoft Word format.

Entries should also include the student’s name, address, telephone number, law school, expected graduation date, and the following signed statement: “I declare that during the 2015-16 academic year, I was enrolled and in good standing (i) at a Virginia law school, or (ii) at a law school outside Virginia as a Virginia resident. I further declare that this entry was written solely by me while enrolled and in good standing in law school.” The student author’s inclusion of this statement in the transmittal email, together with his or her typed name between two forward slashes (i.e. /Jane M. Doe/) shall constitute a signature for the purpose of the signed statement requirement. Deadline All entries must be sent by email to tbranscom@cowanperry.com and must be received no later than 4:00 P.M. Eastern Daylight Time on Friday, May 20, 2016. For problems with transmission, please contact Tara A. Branscom at 540-777-3459. Judging Entries will initially be judged by members of the Section, in their sole discretion, who will select no more than five finalists.

The final judge will be the Honorable Richard Linn of the U.S. Court of Appeals for the Federal Circuit. Judge Linn will select the winner, in his sole discretion, from among the finalists. Criteria for judging include: • Subject matter originality • Relevance to intellectual property practice • Quality of topic development • Analysis of the subject matter • Quality of writing • Proper reliance on cited authorities • Clarity of expression • Grammar, spelling and vocabulary

The winner will be announced no earlier than August 12, 2016 and no later than September 16, 2016. Presentation of Award The winner will be notified by telephone and electronic mail and will be invited to the Section’s 28th Annual Fall Weekend Seminar, for an award presentation ceremony. Hotel accommodations for that evening will be provided to the winner by the Section.

Other Terms & Conditions No article submitted as an entry in this competition may be published in any other forum until the competition has ended and the winner has been announced. After that time, articles submitted but not selected as the winning article may be published without limitation. The author of the winning article grants the Section a non-exclusive license to publish the article at the Section’s discretion. Other publications of the article by the author must include a footnote acknowledging the award from the Section. By submitting an article in this competition, the student author agrees to be bound by the rules, terms and conditions governing the competition and the award of any prizes therein. The Section reserves the right not to make an award in this competition if no entries of acceptable quality are received.

from Blogger http://ift.tt/1VzV2sG

Posted in Uncategorized | Tagged | Leave a comment

Expert testimony in false advertising cases can rely on studies of other events

Concordia Pharmaceuticals, Inc. v. Method Pharmaceuticals,
LLC, 2016 WL 1464639, No. 3:14CV00016 (W.D. Va. Apr. 13, 2016)
 
Previous
opinion on how announcing a product launch and not following up might be false
advertising discussed here.
  Here,
the court resolves some challenges to the parties’ expert witnesses.  Daubert
requires that expert testimony must be “the product of reliable principles and
methods that are reliably applied to the facts of the case.”  Courts aren’t required to admit opinion
evidence “connected to existing data only by the ipse dixit of the expert,” but
neither must they determine that the testimony is irrefutable.
 
Concordia’s expert Dr. Reisetter, a licensed pharmacist with
a doctorate in pharmacy administration, who also works as a consultant for the
pharmaceutical and medical industries, offered opinions on the market impact
and industry consequences of Method’s submissions to drug databases. Reisetter
had performed extensive research on the effects of database listings on the
perceptions and behavior of pharmacists and doctors. Here, he offered the
opinion that Method’s efforts to list its Me-PB-Hyos products with the
databases “caused the marketplace to believe that there was an actual ‘generic’
or pharmaceutical equivalent for Donnatal appropriate for substitution,” and
that this “set off a series of inevitable downstream events in the marketplace
that adversely affected the number of prescriptions for Donnatal filled and
units sold, despite no such product being available.”
 
Method argued, among other things, that Reisetter improperly relied upon surveys conducted in
other cases (or, apparently, other “research projects”) in forming his
opinions.  While there are valid concerns here—especially for surveys
conducted for other litigation, as opposed to for other research objectives—I
think it’s often a mistake to assume that surveys conducted for a specific
litigation are more reliable than surveys conducted without the specific case
in mind.  Even the techniques we have for
detecting bias are not necessarily very reliable, and if anything, generalized
knowledge about a field might be more useful and predictive. 
 
The court found that exclusion was unwarranted; the issues
could be adequately addressed on cross-examination.  In particular, “[w]hile the court may
ultimately limit the extent to which Dr. Reisetter is permitted to reference
specific responses to survey questions, the court will permit him to offer
opinion testimony based on the results of the prior surveys,” as long as
experts in the field would reasonably rely on these kinds of prior surveys. “The
defendants are also free to point out that Dr. Reisetter ‘s opinions are not
based on quantitative or qualitative research employed to determine actual
market behavior in response to the particular database listings at issue in
this case.” In a footnote, the court said that, because these prior surveys
didn’t “account for the actual allegations in this case,” they wouldn’t support
an implied falsity theory.  It’s this
kind of reasoning that makes me sad—I think appropriately conducted surveys can
tell you how consumers will react to a claim, or a type of claim, even without expensively
testing the exact ad claim at issue in a particular defendant’s advertising.
For example, “Made in USA” is the kind of claim that is likely to work the same
way across products and contexts.  More
generally, elevating surveys over marketing experts creates a false sense of
precision, while raising litigation costs and ignoring on the front end (the
survey requirement for implicit falsity claims) all the weaknesses of surveys
that courts—expensively—deal with on the back end (the particular survey once
conducted, which might well end up being discounted).
 
Method also offered the opinions of Dr. William Fassett, a
licensed pharmacist and a professor emeritus of pharmacotheraphy at Washington
State University with an extensive background. 
In his report, he opined that price increases such as those Concordia
implemented for Donnatal would explain the harm Concordia attributed to
Method’s actions: that the reactions of pharmacists and prescribers to price
increases are generally consistent and that he would expect formularies to
eventually exclude Donnatal, and prescriptions for Donnatal to ultimately
decrease, in response to increased prices. 
As an example, he cited a prescription pain reliever that, like
Donnatal, had no generic equivalent. When the manufacturer increased the price
by over 600%, the results were increased sales dollars, fewer prescriptions and
unit sales, exclusion from formularies, and substitution, “all of which would be
expected with Donnatal.”
 
His opinions were “derived from his decades of experience as
a pharmacist, during which he dispensed Donnatal and its generic competitors;
his extensive experience working with formulary committees; and his specialized
knowledge of how formulary committees make coverage determinations.”  Personal experience is a possible
qualification for an expert as long as he can “explain how [his] experience
leads to the conclusion reached, why [his] experience is a sufficient basis for
the opinion, and how [his] experience is reliably applied to the facts.”
 
The court did exclude a portion of Concordia’s damages
expert’s report dealing with lost profits. Concordia failed to establish that his
lost profit calculations were “the product of reliable principles and methods”
that were “reliably applied” to the particular facts of this case. He failed to
take into account numerous market factors that could have affected Donnatal
sales and prescriptions.  For example,
while he determined that Donnatal prescription volume was “generally unaffected
by price increases,” he limited his analysis to two price increases in 2012, a
time when existing inventories of competing generic products were being
eliminated from the market, and he disregarded another price increase in 2013
that was followed by a reduction in Donnatal prescription volume and unit
sales. This price increase occurred after generics had been removed from the
market, but before Method’s products were listed with the pharmaceutical
databases.  Nor did he consider the
impact of newer drugs available for treating IBS, “which, unlike Donnatal, have
been approved for effectiveness by the FDA.” The expert’s failure to consider
them, or to offer an explanation for his failure, creates “enough of a doubt as
to the overall reliability of [his] opinions as to render them inadmissible.”

from Blogger http://ift.tt/1SmSb2c

Posted in Uncategorized | Tagged , | Leave a comment

Further results from my FOIA case against ICE

With the assistance of Georgetown’s Institute for Public Representation, I sued ICE to get it to answer some questions about why its representative claimed that “X sucks” merchandise would infringe X’s trademark rights, at least where X is a sports team.  ICE has made three productions so far, and it’s basically a lot of blurry pictures and heavily redacted guides produced by sports teams/apparel companies.  Assuming that the sample I have is at all representative, it seems to me that ICE does seize a lot of plain counterfeits, but it can also seize more questionably.  Is this design on a shirt likely to cause confusion about source?


Blunt Blowin’ Bull with bloodshot eyes and marijuana

Certainly, many of the photos showed counterfeits, including counterfeit tags claiming to be genuine NFL etc. merchandise.  With the caveat that the organization of the production makes start/endpoints for different seizures difficult to determine, there was one seizure centering on Seattle Seahawks merchandise that didn’t follow this pattern.  There didn’t seem to be counterfeit tags–ICE didn’t produce photos of tags for this seizure, and their practice is apparently to photograph tags when they might be counterfeits.  Some of this merchandise bore Seahawks logos alone; others involved Seahawks-related images, or a logo plus other positive/fannish commentary.  Many of those shirt didn’t look particularly official to me; they might make good examples for discussion of trademark as a pure merchandising right, which ICE is helping to protect.

Superman/Seahawks

Seahawks with list

Match-up with both teams’ logos

Go Hawks Re-Pete

I have no idea what’s going on here; suggestions very welcome

Why not us?

from Blogger http://ift.tt/1SVonK7

Posted in Uncategorized | Tagged , | Leave a comment

Comments on section 512 from the OTW and a few others

The Copyright Office has posted the responses to its notice of inquiry on 512.  Here’s the Organization for Transformative Works comment on 512.  Also, among the 90,000+ responses, there are comments from Eric Goldman, and a comment based on the empirical work of the Takedown Project.  If anyone wants my collection of downloaded long-form comments, let me know and I’ll send you the Dropbox link.  I’m sure there will be many interesting submissions in there. And a lot of grandstanding from practically everybody.

from Blogger http://ift.tt/1qAFTdK

Posted in Uncategorized | Tagged , , , | Leave a comment

announcing product launch and pricing can be false advertising if no launch occurs

Concordia Pharmaceuticals, Inc. v. Method Pharmaceuticals,
LLC, 2016 WL 1271082, No. 3:14CV00016 (W.D. Va. Mar. 29, 2016)
 
Concordia bought the Donnatal line of pharmaceutical
products from former plaintiff PBM. Donnatal is a prescription line of
combination phenobarbital and belladonna alkaloid (PBA) products that is used in
the treatment of irritable bowel syndrome and acute enterocolitis. They’re
grandfathered drugs; the FDA was required to conduct a retrospective evaluation
of such drugs in 1962.  Concordia
benefits from conditional approval ANDAs that allow Donnatal to be legally
marketed until the FDA resolves questions regarding the drugs’ effectiveness
under the FDCA; the FDA has concluded that Donnatal is safe.
 
Donnatal faced competition from generic PBA products that
were pharmaceutically equivalent to Donnatal for many years, but then
manufacturers of the generic versions began to take their products off the
market, making Donnatal the only PBA product available for prescription.
 
Method, a wholesale drug distribution company, tried to
enter the market with a PBA product it planned to call Me-PB-Hyos, and sought a
manufacturer for a product that would be pharmaceutically equivalent to
Donnatal. Method issued four purchase orders to another company, Winder, for
the development of Me-PB-Hyos, including a purchase order for stability tests.
Winder and Method agreed on the price that Winder would charge and discussed
commercial production.
 
Method listed the Me-PB-Hyos products with two
pharmaceutical industry databases, used nationwide by wholesalers, third-party
payors, pharmacies, and pharmacists.  Based
on the information provided by Method, the Me-PB-Hyos products were assigned
the same Generic Product Identifier as Donnatal by one database, with a marketing
start date of June 1, 2014, and the marketing category was listed as
“unapproved drug other.”  The other
database listed the Me-PB-Hyos products in early June 2014.  In both databases, the price information
provided by Method indicated a lower price than that for Donnatal.
 
This lawsuit began, and Method contacted Winder, stating “We
think it might be best to bail on this project at Winder and not bring Winder
into the litigation.”  On the same day,
Method advised one of the databases that “Me-PB-Hyos is an active product and
will be available to ship by 11/15/14.” Following up, Method explained that “The
products were never launched. Within days of our listing with Medi-Span back in
April, Method was sued by a competitor… Based on the status of the case, Method
intends to launch in mid-November.”  But
it never did, and about a month later, the databases removed their active
listings for the Me-PB-Hyos products.
 
After the Me-PB-Hyos products were listed on the databases,
pharmacists began to submit claims for the product.  There were instances in which insurance
coverage for Donnatal was refused; at least once, a claim for Donnatal was
refused while a subsequent claim for Me-PB-Hyos was approved. But because
Me-PB-Hyos was unavailable, the patient was switched to different medications
and didn’t receive a prescription for Donnatal. 
Third-party payors began placing Me-PB-Hyos on their formularies as a
generic alternative to Donnatal, and at least once Donnatal was actually
removed from a formulary with Me-PB-Hyos listed as the preferred generic
alternative.  Some doctors stopped
prescribing Donnatal altogether based on the mistaken belief that it was no
longer available. One doctor testified that “12 or 14 prescriptions … were
turned down” in June of 2014, and that she “slowly stopped writing
[prescriptions] because [she] didn’t want to get the phone calls back” from
pharmacies indicating that Donnatal wasn’t available.  The total number of Donnatal prescribers decreased
by nearly eighteen percent in the twelve-month period following Method’s
claimed launch date, and weekly prescription counts for Donnatal also
decreased, though the causation was disputed.
 
From January 2012 to June 2014, the prices of Donnatal
products increased by 1,480%, and then in June Concordia doubled the price
again.  Its profits and profit margin
increased after Method’s Me-PB-Hyos products were listed with the databases,
though Concordia argued that it would have made even more had Method not listed
its products.
 
Concordia argued that the listings were literally false,
since no Me-PB-Hyos products were ever manufactured.  Method responded that the mere existence of a
listing for a product in a pharmaceutical drug database is not a representation
of current commercial availability, and that at least one pharmaceutical
industry representative deposed by Concordia testified that it was common to
find a database listing for a product that was not yet commercially available. Concordia’s
own pleadings stated that databases are “used … to evaluate medications that
are currently or will soon be on the market.”  There was a genuine issue of material fact
about literal falsity as to availability; a reasonable jury could conclude that
there was literal falsity by necessary implication.
 
Concordia also argued that  Method made literally false statements
indicating that the Me-PB-Hyos products had been approved by the FDA, because
the package inserts included the following: “FDA has classified the following
indications as “possibly” effective: For use as adjunctive therapy in the
treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous
colitis) and acute enterocolotis ….” 
Method responded that it never claimed that its own product had been
approved, and specifically advised the listing services of the absence of FDA
approval (thus the category “unapproved drug other”).   Its reference, Method argued, was to PBA
drug products, and it noted that product labels and package inserts for other
generic PBA drug products previously on the market contained similar language.  The court still found a factual issue as to
literal falsity: “reasonable minds could differ as to whether FDA approval was
conveyed by necessary implication as a result of the indications and usage
section of the package inserts.”
 
Concordia also argued that Method made false claims of
pharmaceutical equivalence, because it had no products with the same active
ingredients in the same amounts—it hadn’t produced anything.  (Isn’t this really an unusual lack of
substantiation claim?  Before there is a
product, it seems that it’s neither true nor false that the product is
pharmaceutically equivalent.  The product
isn’t.  That doesn’t mean it’s not pharmaceutically equivalent, because the failure to be comes before it could be evaluated as
equivalent or not.)  Indeed, the court’s
phrasing makes clear that this is a lack of substantiation claim: “Concordia
argues that Method had no basis for
the information contained in the labels and inserts” (emphasis added).  Method argued that it intended to distribute
a pharmaceutically equivalent product, and was only halted by this
lawsuit. 
 
The court again found a material issue of fact, hinging in
part on whether Method falsely represented that the products were commercially
available.  If a jury so found, it could
also find the descriptions of ingredients to be literally false.  But if the listing merely indicated an intent
to market, a jury could find that there was no literal falsity. 
 
The court went through the same reasoning with respect to
Method’s price claims.
 
Materiality: assuming that the Fourth Circuit would require
a showing of materiality even in cases of literal falsity, there was a genuine
issue of material fact on materiality. A jury could find that claims of
pharmaceutical equivalence, price, FDA approval, and availability were likely
to influence purchasing decisions.  So
too with harm, even without Fourth Circuit guidance on when a presumption of
harm might be allowed, given the (contested) evidence of harm recited
above.  (There was other evidence of
alternative causes—for example, “Donnatal was pulled up with no generic product
showing” at three major pharmacy chains, and the doctor who testified might
have been told that Donnatal was no longer being made because one version had in
fact been discontinued.)
 
State-law unfair competition claims survived for the same
reason, but not Virginia Consumer Protection Act claims, because that law
doesn’t provide competitors with standing. Likewise, unjust enrichment failed
because there was no evidence that Method received any value from using
Donnatal product labels to create its own labels.  (Anyway, that theory sounds like a FDCA
preemption claim waiting to happen.) Nor could conspiracy claims survive;
employees of a corporation can’t conspire with the corporation, and there was
no evidence that Winder was part of any conspiracy; even though it knew that
Method wanted to make a competing product, there was no evidence that it knew
about the database listings, the only source of harm here.  Tortious interference also failed for want of
evidence of any specific, existing contractual relationship or business
expectancy that was destroyed.
 

from Blogger http://ift.tt/1oF9kt3

Posted in Uncategorized | Tagged , | Leave a comment

“Excessive use of professional reviewers” might be false advertising

Interlink Products Int’l, Inc. v. F & W Trading LLC, No.
15-1340, 2016 WL 1260713 (D.N.J. Mar. 31, 2016)
 
The parties compete to sell showerheads; Interlink claims
rights in the marks AQUASPA, AQUASTORM, AQUADANCE, and SPIRALFLO for showerheads.
 It sued F&W for false advertising,
trademark infringement, and related claims, and F&W counterclaimed for
false advertising etc. based on Interlink’s allegedly false representations of
compliance with the Energy Policy Act, which sets flow rate requirements for
showerheads. 
 
On the counterclaims, F&W argued that the product
instructions constituted actionable “advertising or promotion” because they
“serve the purpose of influencing the customer who purchased the item to
continue purchasing Interlink showerhead products and to also influence other
potential customers who become aware of them through contact with the initial
purchaser.” The court disagreed, finding that product inserts were post-sale
and didn’t influence consumers in their purchasing choices.
 
Interlink argued that F&W shouldn’t be allowed to
proceed on claims based on Interlink’s alleged violation of the Energy Policy
Act, because F&W didn’t plead that it itself complied with the standards
and couldn’t plausibly allege damages. 
The court disagreed.  If consumers
chose Interlink over F&W based on the allegedly false claims, F&W may
have suffered damages.
 
Tortious interference: F&W argued that Interlink
purposely used black image backgrounds instead of white ones in its Amazon
sales, against Amazon policy.  But “F&W
provides no support for its argument that the violation of a website’s image
requirements gives a third-party user of the website a cause of action for
unlawful competition. Interlink’s compliance with Amazon’s image requirements
is a matter Amazon.com and Interlink.”
 
The court did decline to dismiss claims based on Interlink’s
alleged failure to mark showerheads with their country of origin, given
F&W’s admission that at least some of its showerheads were also not marked;
F&W argued that it was now in full compliance with the law, which was
enough to avoid dismissal.
 
Turning to Interlink’s claims, Interlink alleged that
F&W used Interlink’s pictures and product descriptions, thus falsely
advertising their own products.  F&W
argued that the pictures used showed the different functions of the showerhead
and that Interlink didn’t allege that the functions were unavailable in
F&W’s products or that the F&W products were inferior.  But Interlink’s argument was that F&W was
misrepresenting that their product was in fact Interlink’s product (or that
they were of the same nature and quality), and that’s a violation of
§43(a).  (Ah, but (1)(a) or (1)(b)?)
 
Defendants also allegedly misrepresented that AQUAFLOW was a
registered trademark; defendants rejoined that the ® symbol was used by mistake
and that they’d ceased using the trademark symbol. Citing McCarthy’s statement
that the “use of … the ® adjacent a mark not federally registered is … a form
of false advertising which may result in serious repercussions,” the court
found that Interlink had pled a plausible claim for false advertising.  (Why is this plausibly material?)
 
Interlink also alleged that defendants manipulated product
reviews, and thus numerical product ratings, “through the excessive use of
professional reviewers” who were flooded with free samples, leading to reviews
that “are inherently biased and tend to favor the seller.” That was enough to
state a claim for implied falsity.  (What
exactly is the falsity?  Assuming that
the free sample was disclosed, is “bias” something more than puffery?)
 
Interlink also sufficiently alleged false advertising by
pleading that: (1) defendants advertise that the installation of their dual
showerhead requires “absolutely no tools”; (2) this statement is “literally
false”; and (3) the product instructions “clearly instruct the purchasers to
use” tools.
 
However, as a non-consumer (purchases made for purposes of
this litigation didn’t count), Interlink lacked standing under New Jersey
consumer protection law.
 
The court also found Interlink’s trademark confusion claims
based on defendants’ AQUAFLOW compared to its marks AquaSpa and SpiralFlo
plausible.  Given how descriptive those
terms are, that seems like a troubling result, but the court here doesn’t seem
inclined to ask for much from either side here. 
Interlink also alleged trade dress infringement of a trade dress
comprising:
 
(1) The use of circular pictures
arranged in a vertical column showing the various function modes of the
showerheads, together with the terminology used to describe the functions and
the font and positioning of the function descriptions beneath the pictures;
(2) photographs of Interlink’s
products;
(3) the look, feel and style of the
presentation of product images;
(4) the non-functional aspects of
the design of the products, specifically the shape of the shower handle, head
and shower jet design …; and
(5) the trademarks used in
connection with the products.
 
Interlink adequately alleged non-functional elements—the package
design’s use of circular pictures in a vertical column with certain fonts,
words, and pictures, along with Interlink’s trademarks. 

from Blogger http://ift.tt/1qvznoE

Posted in Uncategorized | Tagged , | Leave a comment

Copyright Registration Practice with Robert Kasunic

Copyright Registration and the Compendium
Robert Kasunic, Associate Register of Copyrights and
Director of Registration Policy & Practice, U.S. Copyright Office
 
25th anniversary of Feist.  Cornerstone of his
approach to copyrightability.  Feist isn’t a telephone book case; it’s
the only post-1976 case focusing on originality and what constitutes a creative
act of authorship.  It also explicitly
stated that originality is a constitutional requirement.  Neither Congress nor courts can protect a
work without sufficient originality, and Office can’t register.  Court stated that the amount of creativity
required is low; most works make the leap easily, but some works won’t.  Alphabetizing is a type of creativity that
won’t qualify. Also, time/effort/expense aren’t relevant to
copyrightability.  Distinction b/t
creative authorship and discovery of facts.
 
Feist didn’t
answer all questions—even questions about yellow pages: selection of categories
enough? What if they’re garden-variety categories?  If there are creative categories,
registration ought to be allowed, but how creative can telephone directory categories
be? The more creative they are, the less useful it will be.  We received a claim in a medical x-ray as a
photo: but how many patients desire creative x-rays? Impetus for creation is
discovery or functionality; that doesn’t mean that some x-ray could be created
creatively, but mostly they’re done to discover facts, just like the census
taker in Feist.
 
Yellow pages are typically alphabetical, but raise issues
about collective works as opposed to compilations of facts. An ad in a
directory could be sufficiently creative in image or words to be copyrightable.
But unless selection, coordination, and arrangements is sufficiently creative,
they’d need to be registered separately rather than together as a collective
work.
 
Feist’s principles
have to be translated to all categories of works: a circular arrangement of
diamonds on a ring is equivalent to alphabetizing in its typicality.  Examiners decide more claims every day than
federal courts adjudicate in a year—80 examiners and ½ million claims per year.  We see difficult/novel claims on a regular
basis—individual performance of actor in film; DNA sequences depicted in photos;
social dances; end-zone routines; online criticisms of doctor claimed by the
doctor; tweets; compilations of tweets; all the recorded notes of an electric
piano; jingles; interior designs for apartments; floral arrangements; edible
arrangements; cheerleader uniforms. Creators often don’t understand copyright
law and often aren’t interested in learning the nuances.
 
Common area of confusion: work made for hire.  Many people would love to be hired, but don’t
understand this is a term of art.
 
Examiners need to explain their refusals—Atari court was very concerned with
this.  Allowances don’t have to be
explained, but we now annotate certificates to show where we thought there was
an important ambiguity because registrations are presumptive evidence of
validity.  95% are registered easily. But
some works in every category of authorship may not make the grade.  This result is “neither unfair nor
unfortunate.” It’s the means by which © advances the progress of science &
useful arts.  Examiners must remain
diligent; it would be easy to be a rubber stamp and let the courts weed out
5%. 
 
Subject matter issues: dances; movements (yoga poses);
performance of actor copyrightable as dramatic work?  Do the statutory categories serve as a limit
on copyrightability?  Feist: Court demonstrates careful
reading of all the words in statute,
to make clauses consistent w/other clauses. 
Significant example: June 22, 2012 Fed. Reg. statement of policy on
registration of compilations.  Step
towards building on Feist beyond
originality to the limits on the categories of copyrightable subject matter.  Being a compilation isn’t enough: has to be a
compilation of stuff within the subject matter of copyright.  But is §102(a) limitative?  Many have interpreted the word “include” in
§102 to indicate that the list is just illustrative, but no court has
sanctioned a new category of copyrightable subject matter. Intellectually
honest assessment was required.  Other
empirical evidence: Congress clearly chose not to include some works, such as
typeface or works of industrial design. Choreography was deliberately chosen;
architectural works were added explicitly; if the categories were merely
illustrative, then addition should not have been necessary. So there’s clearly
ambiguity about Congress’ intent, given its own actions.
 
Legislative history: H. and Sen. Reports are identical on
this issue: by using original works of authorship, rather than all writings of
an author, Congress intended to avoid exhausting its constitutional power in
the field. The use of “includes” was designed to preserve Congress’ power in this field. “There are unquestionably other
areas of existing subject matter that this Congress doesn’t choose to protect.”
§102(a) was worded to avoid courts’ struggling with the scope of particular categories, but not to authorize them to create
new categories of authorship.
 
Helped resolve recurring issues about compilations of
noncovered subject matter, such as yoga poses. 
Also shows that registering a catalog of garden sculptures registers the
photos in the catalog, but not the sculptures themselves, which have separate
creativity.
 
Compendium of practices: we strove to clarify many issues,
such as that the creativity in a work must be perceptible in the deposit,
rather than expressed in a creative explanation of the work’s creativity.  Puts Office at odds with CDN v. Kapes and CCC
(Red Book) case—courts stated that individual numbers that were the product of
various creative processes were copyrightable. 
It’s not a fact, but a creative prediction or estimation.  A number as a deposit reveals no selection,
coordination, or arrangement in itself.
 
Some courts have ignored the Office’s role as filter and the
statute by allowing suit upon mere application, not upon acceptance or
rejection of the application. 
Short-sighted.  Nimmer sees this
as no-harm, no-foul because most applications are accepted.  But Feist
counsels otherwise, as the Compendium explains. Expediency is not an excuse for
ignoring the plain language of the statute and the unambiguous legislative
history.  Any applicant in
prospective/pending litigation can pay for expedited service in 5 days.  We mediate a much higher percentage of
applications than 5%. In 40% we either correspond for clarification of
authorship, ownership, WFH, joint work, removal of ambiguous terms,
resubmission on proper form, submission of deposit, payment of proper fee,
limitation based on previously registered/published/public domain material, and
exclusion of authorship not fully owned by the claimant. Thus even claims in
which registrations ultimately issue are regularly changed by the examination.
We increasingly specify the basis on which something was registered—serves as a
check on overclaiming and abuse, as w/doctors seeking to register criticism of
their professional services. The doctors claimed ownership via transfer
agreement, appended to federally required HIPAA notices.  Rejected such claims: apparent involuntary
transfer—doesn’t need to be invalidated by a court; we can do it.
 
Courts that accept pre-registration claims may find
infringement where the registration wouldn’t have been accepted, or would have
been limited.  Many claims are just
abandoned when the Office asks questions about them.  Genetically modified poinsettia: courts can
benefit from Office’s analysis of legislative history and statute; so too with
social dance and yoga.  Also the monkey
selfie.
 
Software: Copyrightability and Registration
Moderator: Michael Carroll, Professor of Law, American
University Washington College of Law
 
Terry Illardi, Copyright Counsel, IBM: Older companies tend
to register more heavily. IBM is 102 years old and has 40,000
registrations.  Mixture of documents and
software; register 500 software programs/year and 1000 documents/year.  IT companies are more mixed than
entertainment companies; one large firm hasn’t registered one work in years;
Microsoft has 3000 registrations. 
Special practices for software source code; object code doesn’t mean
anything to a human being.  Most source
code has confidential/trade secret info, so Office allows special registration
procedures.  Now we do “striping”; the
idea is that you deposit a copy with parts taken out.  Whether it’s effective as registration is a
good question, but we’re happy to be allowed to do it by the Office.  Now we get digital copies of source code and
a program obscures pieces of the code for us. 
Imagine a page of code with diagonal stripes going across the page; you
can see 63%.
 
Software is complicated by different versions: IBM lingo is
the version, the release, and the mod. 
We don’t file for registration on every mod (third position in version
1.0.1), but do for most releases and all versions.  When 5-10% of code has changed, it’s time for
a new version.  Other companies
don’t.  You could do it for availability
of attorneys’ fees, etc., but IBM doesn’t bring a lot of lawsuits, so that’s
not a compelling reason.  Valuable to our
litigation dep’t for defensive purposes—can find information that generally
helps our case; we get sued more than we sue. 
Registration also provides proof of ownership, and where this is
important is with certain foreign gov’ts that require proof that software
you’re licensing is yours. The easiest way to show that is a bunch of
registration certificates.  Makes deals
go through more quickly—pays for the practice. 
Similar experience w/ foreign tax authorities and transfer taxes.  Also useful in divestitures, which happen
many times a year; provides proof that what we’re divesting we actually own.
 
Chris Mohr, Vice President for Intellectual Property and
General Counsel, SIIA: Obscuring source code is real priority for members.  Would also really like to see modernization
of the Office.  Increased security for
deposits in an upgraded system (we wish).
 
Carroll: TRIPS requires protection for computer programs as
literary works under Berne.  But what
about the Internet of Things?  Software
is embedded in a thing.  How should that
work?  Does it make sense to ask for
first/last 25 pages where programming art has changed so much? What should 21st
century deposit look like?
 
Illardi: We are in the age in which software is put together
like Lego blocks: old pieces snapped into new configurations.  Companies have found efficiencies in reusable
components/libraries.  Open source is
also a source, following the rules of the licenses.  There usually is a beginning of a program,
nonetheless, so there’s still some vitality to the old rule; not clear how
useful the last 25 pages is b/c that can be almost anything.  But to the extent that you can compare to the
deposit copy to prove infringement, even if the code shows up in a different
position, that’s useful; not clear to him there’s a better alternative.  Programs have 10s of thousands of level
blocks—some a dozen lines, some 100,000 lines. Shouldn’t have to deposit/pay
for each one.  Maybe a rule about the
biggest blocks of code?
 
Carroll: what about encrypting them in a hash?
 
Illardi: interesting, though might not allow comparison with
copied works which could be copies w/o having the same hash?
 
Q: isn’t the purpose of © deposit also to disclose?  If it’s obscured, how will it ever enter the
public domain?
 
Illardi: only keep copies for a limited time anyway.  So the Office’s procedures won’t help
historians anyway.
 
Kasunic: for published works, we keep for 30 years; it had
been much shorter. 
 
Q: the deposit copy may not help with actual litigation,
where you have to show they copied what you registered.
 
Carroll: software is iterative; the Office is clear that a
registration for 1.0 will not cover a prior version unless it’s
unpublished.  If prior version is
published, you have to be very clear about what you’re claiming as the
registrable material.  So how does the
IBM process work?
 
Illardi: careful records kept internally of what the changes
are.  Document filled out by developers
and reviewed by lawyers.
 
IBM’s focus has historically been on freedom of action;
relationship with Dep’t of Justice meant that it had to give others access to
its patents, and wanted access to others’ in return.  Our focus today may be relatively more on
enforcement, but only relatively.
 
Carroll: Looming question: will we have to reconfigure the
practices and understanding for internet of things?  Current definition of computer used by Act (which
then tells us what software is) requires an output on a screen/display or
printer, but not all IoT objects will do that.
 
Mohr: the Office had an inquiry on embedded software, and
registration didn’t really come up at all in the comments he looked at.  The answer may be that computer programs can
be embedded in machines, but it’s a question that needs an answer more detailed
than we can give right now.
 
Illardi: may need to rethink definition of computer;
smartphone is a computer that matches the current definition, but many things
won’t b/c they’re meant to work with something else.  Fitbit is meant to have an output, but the
output shows up on another machine.
 
Copyright at the Edges
Moderator: Peter Jaszi, Professor of Law, American
University Washington College of Law
 
Rebecca Tushnet, Professor of Law, Georgetown Law Center
Copyright puzzles: A “useful article” is an object having an
intrinsic utilitarian function that is not merely to portray the appearance of
the article or to convey information.  Is
a jigsaw puzzle a useful article? 
Copyright Office guidance: “No matter how novel, distinctive, or
aesthetically pleasing any clasps, motors, or other functioning parts
of an article may be, copyright does not protect them…. Articles whose
intrinsic purpose is to portray a useful article or convey information—such as toys,
scientific or fine-art models, newspapers, architectural plans, and maps—are
not useful articles
and may qualify for copyright protection. But
protection would not extend to any mechanical or utilitarian parts
they may
have.”
 
So, is any connector between two things functional? If
that’s the case, then interlocking jigsaw puzzle pieces seem functional: they
make the picture hold together, much as the spine of a book holds the pages
together.  Other interesting questions: Computer-generated
artworks (if artworks they are) where the piece shapes are determined by
mathematical algorithms, and then perhaps hand-tweaked.  Copyrightable?  Here’s a real case where the output is
independently valuable, compared to the program itself; the program’s obvious
copyrightability doesn’t matter very much if a copier can use the output freely
because there’s no human authorship in the output.
 

Computer-generated puzzle

Second puzzle made out of blue pieces of first puzzle

Separately: If the pleasure added by the jigsaw puzzle to
the image is haptic, then isn’t it more like a chair with a picture printed on
it (or like a skateboard with an image printed on it, for that matter, another
non-necessary item that is nonetheless a “useful article”) than like a
sculpture?  Things US copyright generally
doesn’t cover: Perfumes; soft woven scarves with specially pleasing textures;
recipes.  Cf. Christopher Buccafusco, Making Sense of Intellectual Property
Law
, 97 Cornell Law Review 501 (2012); he has a followup
article here
which I will shortly read.
An unassembled Liberty puzzle

Liberty puzzle, assembled
 
 
Stave puzzles—the image intertwined with the cut.  Is it a sculpture?  If the cut isn’t part of the work, then someone else might be able to copy the cut even though they can’t copy the image.
 

Color line cutting
Color line cutting:
integrated with the picture in another way, in order to trick the eye or
delight the puzzler when the piece falls into place.  Do these techniques mean that puzzle cuts
might be derivative works of the image, with creativity that intertwines with
the expression of the image?
 
Comments indicated that some people would just try to
register the cut as a 2D image, though I think that wouldn’t give you rights to
control the cut if a puzzle is a
useful article.  The puzzle does what it
does because the design is cut into different pieces.  Back to the question: Does giving
intellectual/haptic pleasure do something more than conveying information?  I wouldn’t say petting my cat conveys
information, but it certainly provides tactile pleasure.
 
Tom Kjellberg, Counsel, Cowan Liebowitz & Latman
Separability seems to set a higher bar for copyrightability
than something that’s treated as purely aesthetic: pure abstract art in the
ordinary 2D and 3D senses is usually protectable; would have higher bar as
useful articles.  Jewelry easy; button
harder.
 
Newspaper is useful, but not a useful article because its
intrinsic function is to convey information. 
3 separability cases sought cert.; the cheerleading uniform case is
scheduled for conference this month. 
Inhale v. Starbuzz: 9th Circuit gave Skidmore deference to
Office’s holding that distinctiveness of shape doesn’t affect separability; any
part of a container that merely accomplishes containment isn’t
copyrightable/separable.  [Which seems to
me to have implications for my jigsaws …]
 
Legislative history: a 2D graphic work is still capable of
being identified as such when it is printed on or applied to utilitarian
articles such as textile fabrics, wallpaper, containers, and the like.  [This is why I think the cheerleading case
should have been decided on originality grounds, not separability grounds; the
basic stripes just aren’t creative enough to pass through the copyright
turnstile, but some other stripe arrangement might well be.]
 
Mannington Mills: heavily photoshopped photo of wood
flooring used in laminated wood flooring. 
Designers chose particular planks, colored them, aged them, arranged
them into aesthetically pleasing patterns; manipulated hi-res photos to create
the pattern. Registered as 2D artwork. Court of appeals found it both
physically and conceptually separable. 
The design doesn’t perform the function of hiding wear; the layer on
which it’s printed performs the function of hiding wear.
 
Varsity Brands v. Star Athletica: involved in this case from
the beginning, including having registered some of these designs.  Created by in-house designers.  How to characterize what it is we’re claiming?  Don’t want protection for the drawing of the
uniform; want protection for the uniform. 
Settled on “design on garment.”  District
court said this was a utilitarian object: nothing more than a cheerleading
uniform.
 
But what is a useful article?  The function of the uniform design is to
convey the information that the person wearing it is a cheerleader, which
should take it out of the category of useful article.  (The function of the uniform is to cover the
body, so in the first instance a shirt/skirt is a useful article.)
 
Q: Male cheerleaders just wear a T-shirt—so you can convey
“I’m a cheerleader” in other ways. 
Should the design on a T-shirt have a separate copyright?
 
A: no, the © is in the 2D graphic work that appears on the
surface.  Could be a maple laminated floor
pattern!
 
There is no circuit split, just different analytical tests
on separability; just as there isn’t a split on substantial similarity just
because the 9th and 2d Circuits express the test differently.  [I note that the SCt suggested in B&B that there might be a similar
problem with the trademark infringement multifactor test.] The 2d Circuit alone
has taken multiple approaches; it’s subjective/you know it when you see it, and
maybe should be revisited once more important issues in © have been resolved.
 
Carroll: isn’t there a split with the Harrod’s uniform case,
or do the epaulets in the casino uniform serve a nonseparable function?
 
A: Star Athletica argues that there is a split with this 5th
Circuit decision finding that the designs of casino uniforms lacked
separability, and also pointed to an unpublished 2d Circuit holding on prom
dresses, but in both cases they were talking about the 3D design of a garment,
not a 2D design on a garment.  In the Compendium’s next revision, some
attention should be paid to that.
 
Q: compare your approach to the jigsaw puzzle.  The puzzle has to have a thickness, which the
design on fabric doesn’t.
 
Q: TM can protect the uniforms without ©.  Smack
Apparel
etc.  Recent Santa Claus
w/snow globe in its belly: added enough artistic elements to make 3D thing; cut
off the rights of the original artist, according to the court, b/c the original
artist only had rights in a 2D drawing.
 
Carroll: Doesn’t think the 3D/2D distinction works; it’s
really about the utilitarian function of the uniforms.  The court describes cut of a prom dress, but
also lace—the utilitarian function is to mark the wearer as going to a special
occasion, not to cover the body; same with the design features in the Harrod’s
case and the cheerleading uniforms—social utility. If that’s what makes it
useful, 2D and 3D isn’t important.
 
A: definitionally, it’s some blend of portraying its own
appearance and conveying information. So that’s true, but that doesn’t make it
a useful article.  [What if a sports car
conveys the information “I am insecure in my masculinity,” as well as providing
transportation?  We know that the sports
car is a useful article but so is a cheerleading uniform, because it provides
transportation/covers the body respectively. 
What we’re asking is what’s separable from that useful article.]  2d Cir. distinguishes between dress designs
as a term of art and fabric designs, which doesn’t just include a design
printed on a bolt of fabric but also little squirrel appliques on the sweaters.
So 2D v. 3D does some work.
 

from Blogger http://ift.tt/1oF9j8s

Posted in Uncategorized | Tagged , , | Leave a comment

Organization for Transformative Works fundraising drive

Organization
for Transformative Works membership drive
: of possible interest to
law-types in particular, we submitted over 100,000 words on 3 continents in
2015 in support of transformative noncommercial use.  (Wow.) 
Please support the OTW with a donation!

from Blogger http://ift.tt/1qvKCwS

Posted in Uncategorized | Tagged , , | Leave a comment

Go to the mattresses: Tempurpedic wins TRO against Goldilocks claim

Tempur Seal Int’l, Inc. v. Wondergel, LLC, 2016 WL 1305155,
No. 5:16-cv-83 (E.D. Ky. Apr. 1, 2016)
 
The parties compete to sell mattresses.  Wondergel created a comparative ad featuring
a Tempurpedic mattress, though not identifying it by name.  During the ad, Wondergel’s Goldilocks character
“makes derogatory statements about the Tempur-Contour mattress and falls back
on to the mattress ‘in a manner and accompanied by a facial expression and
sound effects that suggest that the mattress is extremely hard and painful for
those who use it.’” This video received over three million views on YouTube.com
and over 14 million views on Purple’s Facebook page; it was shared over
fifty-three thousand times and also appeared (via a YouTube embed) on Purple’s
commercial website, onpurple.com.
 

Grimace of pain

The court granted a TRO against the ad. The objectionable
elements came from the image and the dialogue: “Looking for some shoulder pain?
Try a hard mattress. It may feel like a rock and put pressure on your hips, but
it’s the perfect way to tell your partner: ‘Hey baby, want some arthritis?’”  Goldilocks also referred to the hard mattress—a
Tempurpedic—as a “prison bed.”
 
The court found that these statements were likely to be
false or misleading. The actor suggested that the mattress caused shoulder pain
was “rock hard,” puts pressure on the hips, and may cause arthritis. “The Court
has considered Defendants’ argument that the entire commercial is obviously in
jest, but the Court unaware of any ‘humor exception’ that would make literally
false statements acceptable under the Lanham Act.”  These statements “can hardly be considered
puffery, as these statements regarding potential negative health effects
clearly cross the line beyond what is permissible advertising.”  (But would reasonable consumers receive the
message that the “hard” mattress was literally
hard as a rock, or that it was in fact used in prisons?  Also, what is the evidence that the
Tempurpedic mattress does not “put pressure on” the hips?)  The court was influenced by the negative cast
of the comparison, as compared to flattering puffs.
 
Wondergel argued that the mattress wasn’t sufficiently
recognizable as plaintiffs’ product, but plaintiffs provided sufficient
evidence of consumer recognition of its trade dress. Also, Purple’s
representative stated in a YouTube public comment section that “Tempurpedic was
the hard mattress in the video.”
 
The court presumed irreparable injury from likely success on
the merits, a dubious presumption post-eBay,
and noted that the Goldilocks video had been “wildly popular.” A TRO wouldn’t
block Wondergel from advertising, and would protect the public.

from Blogger http://ift.tt/1Sc6kfz

Posted in Uncategorized | Tagged | Leave a comment

No mark, no false designation of origin is still the rule in NY

Innovation Ventures, LLC v. Ultimate One Distributing Corp.,
2016 WL 1317524, No. 12-CV-5354 (E.D.N.Y. Mar. 31, 2016)
 
The Fourth Circuit’s Belmora
decision did more than create protection for foreign marks in the US; it
created a conflict with a number of other doctrines about who can sue for
trademark infringement.  Here, the
district court follows Second Circuit precedent—but this case clearly should
come out the other way under Belmora,
given the harm the plaintiff concededly suffered.
 
Innovation sued lots of businesses allegedly involved in
making, selling, and distributing counterfeit 5-hour ENERGY.  Quality King is a New York-based wholesaler
of health, beauty, and grocery products, and FDI is a Florida-based wholesaler
of grocery products. Quality King bought approximately 878,688 bottles of what
FDI sold as 5-hour ENERGY, for a total price of over $1,000,000. FDI didn’t
dispute that all of these bottles were counterfeit. Quality King resold
approximately 270,864 bottles to downstream retail customers. (Quality King
56.1 ¶ 13.) The 607,824 counterfeit bottles that Quality King did not resell
were quarantined and transferred to the custody of Living Essentials; Quality
King paid FDI $799,266.80 for the counterfeit bottles that were unsold and
quarantined.
 
Quality King’s standard purchase order included
representations by FDI that “any and all merchandise that is the subject of
this purchase order (1) was obtained by Supplier [FDI] without fraud,
misrepresentation or violation of any statute, regulation, or administrative
court order, (2) can lawfully be distributed in the United States in its
present form and packaging, and (3) is not the subject of any legal or
contractual restriction on its resale by Supplier [FDI] to [Quality King].”  Also, FDI warranted and represented that FDI’s
products were genuine and not counterfeit, and FDI agreed to indemnify Quality
King for costs, expenses, losses, and attorneys’ fees for any lawsuits arising
out of FDI’s breach of the Vendor Agreement.
 
The court found that Quality King was entitled to summary
judment on its breach of contract/warranty claims in the amount of $799,266.80,
with factual disputes precluding determination of any additional damages at
this time. However, common law indemnification for the Lanham Act claims
against Quality King was unavailable, because indemnification “is neither
provided for under the Lanham Act’s extensive remedial provisions nor has
federal common law been implied to allow such remedies.” Moreover, “a party who
has itself participated to some degree in the wrongdoing cannot receive the
benefit of the [common law indemnity] doctrine.” “Common law indemnification is
warranted where a defendant’s role in causing the plaintiff’s injury is solely
passive, and thus its liability is purely vicarious.” Here, Quality King resold
hundreds of thousands of the counterfeit bottles, thus participating in some
degree in the wrongdoing.
 
Quality King also sued under §43(a)(1)(A) and (B).  The court rejected the false desgination of
origin claim because Quality King didn’t own or have a property interest in any
relevant trademark rights. “[I]t is well settled that the standards for false
designation of origin claims under Section 43(a) of the Lanham Act (15 U.S.C. §
1125) are the same as for trademark infringement claims under Section 32 (15
U.S.C. § 1114).”  Cf. Greenwich Taxi,
Inc. v. Uber Tech., Inc., 123 F. Supp. 3d 327, 338 (D. Conn. 2015) (dismissing
federal false designation of origin claim where plaintiffs failed to allege
their “associat[ion] with any recognizable marks or associat[ion] with valid
marks entitled to protection”); Zino Davidoff SA v. Selective Distrib. Int’l,
Inc., No. 07-cv-10326, 2013 WL 1234816, at *7 (S.D.N.Y. Mar. 27, 2013) (“simply
purchasing a product for resale does not give rise to an interest in that
product’s trademark sufficient to state a claim for unfair competition”);
Silverstar Enters., Inc. v. Aday, 537 F. Supp. 236, 241 (S.D.N.Y. 1982)
(dismissing Lanham Act trademark infringement claim where plaintiff sought to
enforce its own contractual rights rather than registrant’s trademark rights). Quality
King argued that it didn’t need to own the mark at issue to win a false
designation claim, but Second Circuit precedent disagreed with it.
 
False advertising: Lexmark
requires “an injury to commercial interest in sales or business reputation
proximately caused by the defendant’s misrepresentations.”  Quality King argued that two customers,
Steerforth and CVS, ceased purchasing products from Quality King “[a]s a result
of [Quality King’s] sale of alleged counterfeit 5-hour ENERGY,” satisfying its
burden.  The FDI defendants disputed the
losses; the record indicated a material factual dispute about causation.  Moreover, Quality King didn’t show proximate
cause—that its injury was proximately caused by FDI’s misrepresentations, “rather
than Quality King’s independent decision to resell counterfeit 5-hour ENERGY to
CVS and Steerforth. As the Supreme Court cautioned in Lexmark, ‘a business misled by a supplier into purchasing an
inferior product is, like consumers generally, not under the [Lanham] Act’s
aegis.’”  [I think the Lexmark Court pretty clearly meant that
a business that is the ultimate consumer
of the product
is, like consumers generally, not within the Lanham Act’s
zone of interests.  A reseller is a different matter, as the non-competitor
relationship between the parties in Lexmark
itself indicates; also, I don’t understand how Quality King’s decision to resell
to CVS was “independent” of FDI’s misrepresentations.]
 
Regardless, even assuming standing, Quality King couldn’t
show that FDI made statements in “commercial advertising or promotion.” While
Quality King argued that the packaging and labeling on the counterfeit products
was “commercial advertising and promotion,” there was no evidence that the FDI
defendants created or labeled those bottles, or that FDI engaged in a
widespread, organized campaign to mislead the public regarding 5-hour ENERGY. On
the record before the court, FDI’s participation was limited to purchasing
counterfeit 5-hour ENERGY from two wholesalers and reselling that product to
another wholesaler.
 
The state-law unfair competition claim failed because the
standards were the same as for the Lanham Act.

from Blogger http://ift.tt/1Vx6Ytt

Posted in Uncategorized | Tagged , , | Leave a comment